SELENIUM ( DrugBank: Selenium )

4 diseases

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00010842 (ClinicalTrials.gov)	September 1999	2/2/2001	Natural Antioxidants in the Treatment of Multiple Sclerosis	Natural Antioxidants in the Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	N/A	N/A	Both		Phase 1/Phase 2	United States

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100048113	2020-09-01	2021-07-02	Study on the efficacy of selenium supplementation in patients with Crohn's disease and low selenium level	Study on the efficacy of selenium supplementation in patients with Crohn's disease and low selenium level	Crohn's Disease	Experimental group:selenium supplementation;Control group:N/A;	Sir Run Run Shaw Hospital, Zhejiang University School of Medicine	NULL	Recruiting	18	65	Both	Experimental group:60;Control group:30;		China

臨床試験数 : 22 / 薬物数 : 27 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01212965 (ClinicalTrials.gov)	September 2010	24/9/2010	Selenium in the Treatment of Complicated Lymphatic Malformations	Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults	Lymphatic Malformations	Drug: Selenium	Medical College of Wisconsin	NULL	Terminated	14 Years	30 Years	Both	5	Phase 1	United States

臨床試験数 : 98 / 薬物数 : 180 - (DrugBank : 57) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-000087-83-GB (EUCTR)	19/12/2008	04/12/2007	EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2	EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis. - EUROPAC2	Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis MedDRA version: 13.1;Level: HLT;Classification code 10033646;Term: Acute and chronic pancreatitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 13.1;Level: PT;Classification code 10056976;Term: Hereditary pancreatitis;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Magnesiocard 2.5mmol Other descriptive name: MAGNESIUM ASPARTATE HYDROCHLORIDE Product Name: ANTOX (vers) 1.2 Product Code: ANTOX Other descriptive name: TOCOPHEROL INN or Proposed INN: ASCORBIC ACID Other descriptive name: SELENIUM INN or Proposed INN: METHIONINE	University of Liverpool	The Royal Liverpool and Broadgreen University Hospitals NHS Trust	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 3	United Kingdom